Personalized And/Or Generalized Integrated Biomaterial Risk Assessment

akronüüm: PANBioRA
algus: 2018-01-01
lõpp: 2021-12-31
 
programm: H2020 - Horisont 2020
alaprogramm: LEIT - Juhtkoht tööstustehnoloogias
instrument: RIA
projektikonkurss: H2020-NMBP-2017-two-stage
projekti number: 760921
kestus kuudes: 48
partnerite arv: 19
 
lühikokkuvõte: PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of i) new biomaterials under health or disease states or ii) a given biomaterial for each patient in a personalized manner. It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial based applications. PANBioRA will provide a modular platform to assess risks at different aspects and length scales. This comprises antibody response, cytotoxicity/genotoxicity at cell level, systemic and local effects at tissue and connected tissues (organ-on-a-chip) level. Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system. The platform will incorporate standardized protocols yielding significantly more information than the current methods for biomaterial risk assessment. Its accuracy will be demonstrated using known reference materials and validated in a pre-clinical setting. PANBioRA will for the first time, predict the patient specific response to a given biomaterial before its implantation. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes. It will also accelerate the process of validation of the biocompatibility of new devices by providing an automated, comprehensive process for the parallel assessment of risks at different scales aiding new biomaterial discovery and commercialisation. Altogether, PANBioRA will lead to a substantial economic impact due to a reduction of the amount of tests, decrease in healthcare costs due to complications. It will provide the necessary tools proper risk management related to biomaterials.
partneri jrk nr ja roll partneri nimi riik kontaktisik koduleht
1 koordinaator STEINBEIS 2I GMBH DE Timo Doll www.steinbeis-europa.de
2 partner DOLMEN DESIGN AND INNOVATION LIMITED IE www.dolmen.ie
3 partner BIODEVICE SYSTEMS SRO CZ www.biodevicesystems.com
4 partner PROTOBIOS OÜ EE
5 partner ELVESYS SAS FR www.elveflow.com
6 partner STREINBEIS ADVANCED RISK TECHNOLOGIES INSTITUTE DOO KRAGUJEVAC RS www.kg.risk-technologies.com
7 partner Steinbeis Advanced Risk Technologies GmbH DE www.risk-technologies.com
8 partner COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR www.cea.fr
9 partner PRO-ACTIVE BE http://www.nanotechia.org/member/pro-active-sprl
10 partner AALTO KORKEAKOULUSAATIO SR FI http://www.aalto.fi
11 partner TURGUT OZAL EDUCATION SHA AL www.epoka.edu.al
12 partner THE UNIVERSITY OF NOTTINGHAM UK www.nottingham.ac.uk
13 partner AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS ES http://www.csic.es
14 partner DUBLIN CITY UNIVERSITY IE www.dcu.ie
15 partner INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR www.inserm.fr
16 partner CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE BE
17 partner PROTIP MEDICAL FR www.protipmedical.com